Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Feb 20;24(3):165-167.
doi: 10.1177/15357597241232877. eCollection 2024 May-Jun.

Mirror, Mirror on the Wall, Who's the Fairest Third Generation Anti-Seizure Medication of All?

Ioannis Karakis  1
Affiliations
Comment

Mirror, Mirror on the Wall, Who's the Fairest Third Generation Anti-Seizure Medication of All?

Ioannis Karakis. Epilepsy Curr. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author has served as a consultant in a UCB health equity advisory board and a GSK research study.

Comment on

  • A real-world comparison among third-generation antiseizure medications: Results from the COMPARE study.
    Roberti R, Di Gennaro G, Anzellotti F, Arnaldi D, Belcastro V, Beretta S, Boero G, Bonanni P, Canafoglia L, D'Aniello A, Dainese F, De Caro C, Di Gennaro G, Di Giacomo R, DiFrancesco JC, Dono F, Falcicchio G, Ferlazzo E, Foschi N, Franciotta S, Gambardella A, Giordano A, Iannone LF, Labate A, La Neve A, Lattanzi S, Leggio U, Liguori C, Maschio M, Nilo A, Operto FF, Pascarella A, Pauletto G, Renna R, Strigaro G; COMPARE Study Group; Russo E. Roberti R, et al. Epilepsia. 2024 Feb;65(2):456-472. doi: 10.1111/epi.17843. Epub 2023 Dec 16. Epilepsia. 2024. PMID: 38052481

References

    1. Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544–556. doi:10.1016/S1474-4422(20)30035-1. PMID:32109411. - PubMed
    1. Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of “Third-Generation” antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs. 2017;31(11):959–974. doi:10.1007/s40263-017-0480-6. PMID:29204953. - PubMed
    1. Perucca E. From clinical trials of antiepileptic drugs to treatment. Epilepsia Open. 2018;3(Suppl 2):220–230. doi:10.1002/epi4.12239. PMID: 30564781; PMCID: PMC6293126. - PMC - PubMed
    1. Perucca E, Wiebe S. Not all that glitters is gold: a guide to the critical interpretation of drug trials in epilepsy. Epilepsia Open. 2016;1(1-2):9–21. doi:10.1002/epi4.3. PMID:29588925; PMCID: PMC5867835. - PMC - PubMed
    1. Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82(2):199–218. doi:10.1007/s40265-021-01661-4. PMID:35061214; PMCID: PMC8843918. - PMC - PubMed

LinkOut - more resources